Strong Revenue Growth Across the Business
ZBH generated $2,086.7M in revenue in Q1 FY2026, up 9.3% from $1,909.1M in the prior-year period, reflecting solid demand for its orthopedic and medical device products.
ZIMMER BIOMET HOLDINGS, INC. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: ZBH delivered strong Q1 FY2026 results with revenue rising 9.3% YoY to $2.09B and net income surging 30.8% to $238.1M, driven by operating leverage and margin expansion, though cash balances declined sharply by 69.4%.
Drawn from management commentary in the Q1 2026 10-Q:
ZBH generated $2,086.7M in revenue in Q1 FY2026, up 9.3% from $1,909.1M in the prior-year period, reflecting solid demand for its orthopedic and medical device products.
Operating income grew 27.7% YoY to $373.2M, with operating margin expanding approximately 257 basis points to 17.9% from 15.3%, demonstrating meaningful operating leverage on higher revenues despite SG&A rising 12.0% to $849.9M.
Net income increased 30.8% YoY to $238.1M, with diluted EPS rising 34.1% to $1.22 from $0.91, reflecting both improved profitability and the benefit of share buybacks reducing the share count.
Revenue
$2.09B
++9.30% YoY
EPS (Basic)
$1.22
++32.61% YoY
Operating Income
$373.2M
++27.68% YoY
Add ZBH to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.